Advanced glycation end products: a highly complex set of biologically relevant compounds detected by mass spectrometry.

Structural information on 'AGE-peptides,' a class of substances belonging to advanced glycation end products (AGE) and originating by proteolysis of glycated proteins, was gained through various analytical approaches on the mixture produced by proteinase K digestion of in vitro glycated bovine serum albumin. Both matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and high-performance liquid chromatography/electrospray ionization mass spectrometry (HPLC/ESI-MS) were employed, and the results were compared with those from conventional spectroscopic methods (UV, fluorescence, gel permeation). The data acquired by the various techniques all depict the digestion mixtures as highly complex, with components exhibiting molecular mass in the range 300-3500 Da. In the analysis of HPLC/ESI-MS data, identification of AGE-peptides was facilitated by 3D mapping. Structural information was gained by means of multiple mass spectrometric experiments.

[1]  C. Gerhardinger,et al.  Investigation of products arising from enzymatic digestion of advanced glycated albumin by high-performance liquid chromatography/mass spectrometry. , 1991, Rapid communications in mass spectrometry : RCM.

[2]  A. Gugliucci,et al.  Circulating advanced glycation peptides in streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light chains. , 1998, Life sciences.

[3]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[4]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[5]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[6]  R. Flückiger,et al.  Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. , 1986, The Journal of biological chemistry.

[7]  K Nakamura,et al.  Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. , 1997, Biochemical and biophysical research communications.

[8]  V. Monnier,et al.  Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. , 1987, Carbohydrate research.

[9]  R. Dean.  Lysosomal enzymes as agents of turnover of soluble cytoplasmic proteins. , 1975, European journal of biochemistry.

[10]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Lapolla,et al.  The in vitro glycation of lysozyme and the influence of buffer concentration investigated by mass spectrometry. , 1996, Rapid communications in mass spectrometry : RCM.

[12]  Paul J Thornalley.  THE CLINICAL SIGNIFICANCE OF GLYCATION , 1999 .

[13]  A. Lapolla,et al.  Evaluation of IgG glycation levels by matrix-assisted laser desorption/ionization mass spectrometry. , 1997, Rapid communications in mass spectrometry : RCM.

[14]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[15]  K. Maeda,et al.  Mass spectrometric study on the protein chemical modification of uremic patients in advanced Maillard reaction. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[16]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[17]  F. Hayase,et al.  3-Deoxyglucosone Crosslinks Proteins under Physiological Conditions , 1987 .

[18]  E. Diamandis,et al.  Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. , 1994, Kidney international.

[19]  C. Gerhardinger,et al.  A study on in vitro glycation processes by matrix-assisted laser desorption ionization mass spectrometry. , 1993, Biochimica et biophysica acta.

[20]  V. Monnier,et al.  Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.

[21]  S P Wolff,et al.  Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. , 1987, The Biochemical journal.

[22]  V. Monnier,et al.  Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.

[23]  J. Baynes,et al.  Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.

[24]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[25]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[26]  R. Rolandi,et al.  Prevention of Diabetes-Increased Aging Effect on Rat Collagen-Linked Fluorescence by Aminoguanidine and Rutin , 1990, Diabetes.

[27]  H. Sano,et al.  Advanced Glycation End Products and Their Recognition by Macrophage and Macrophage-Derived Cells , 1996, Diabetes.